Epigenetic DNA hypermethylation: Clinical applications in endometrial cancer

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 967-972

  Muraki, Yuriko ^a   Banno, Kouji ^a   Yanokura, Megumi ^a   Kobayashi, Yusuke ^a   Kawaguchi, Makiko ^a   Nomura, Hiroyuki ^a   Hirasawa, Akira ^a   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CHFR; DNA hypermethylation; Endometrial cancer; Epigenetics; hMLH1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; CATECHOL METHYLTRANSFERASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FRAGILE HISTIDINE TRIAD PROTEIN; GENE PRODUCT; PROTEIN CASP8; PROTEIN CHFR; PROTEIN HOXA11; PROTEIN MLH1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CELL; CANCER CLASSIFICATION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CPG ISLAND; DNA METHYLATION; DNA REPAIR; ENDOMETRIAL CARCINOGENESIS; ENDOMETRIUM CANCER; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; MISMATCH REPAIR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSCRIPTION INITIATION;

DNA METHYLATION; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS;

EID: 70449377838     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000523     Document Type: Review

References (33)

1. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000.
2. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
3. Goldberg AD, Allis CD and Bernstein E: Epigenetics: a landscape takes shape. Cell 128: 635-638, 2007.
4. Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231, 2005.
5. Gal-Yam EN, Jeong S, Tanay A, Egger G, Lee AS and Jones PA: Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting. PLoS Genet 2: 160, 2006.
6. Appanah R, Dickerson DR, Goyal P, Groudine M and Lorincz MC: An unmethylated 3′ promoter-proximal region is required for efficient transcription initiation. PLoS Genet 3: 27, 2007.
7. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007.
8. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686, 1999.
9. Kanaya T, Kyo S, Maida Y, Yatabe N, Tanaka M, Nakamura M and Inoue M: Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 22: 2352-2360, 2003.
10. Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A, Tsukazaki K and Aoki D: Relationship of aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep 16: 1189-1196, 2006.
11. Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 6: 212, 2006.
12. Sakaguchi J, Kyo S, Kanaya T, Maida Y, Hashimoto M, Nakamura M, Yamada K and Inoue M: Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer. Gyneol Oncol 98: 427-433, 2005.
13. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK and Goodfellow PJ: Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 9: 2277-2287, 2003.
14. Sasaki M, Kaneuchi M, Sakuragi N and Dahiya R: Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res 63: 3101-3106, 2003.
15. Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, Gaugg I, Goebel G, Müller HM, Mueller-Holzner E, Marth C and Widschwendter M: Methylated DNA collected by tampons - a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 13: 882-888, 2004.
16. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K and Tokino T: Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 100: 7818-7823, 2003.
17. Esteller M and Herman JG: Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 23: 1-8, 2004.
18. Kim JS, Kim JW, Han J, Shim YM, Park J and Kim DH: Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 66: 4049-4054, 2006.
19. Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, Kitago M, Tanemura A, Nguyen SL, Tran AN, Wang HJ and Hoon DS: Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 66: 6692-6698, 2006.
20. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A and Ushijima T: CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 65: 828-834, 2005.
21. Waki T, Tamura G, Sato M and Motoyama T: Age-related methylation of tumor suppressor and tumor-related genes: an analysis of autopsy samples. Oncogene 22: 4128-4133, 2003.
22. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M and Ushijima T: High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12: 989-995, 2006.
23. Ushijima T: Epigenetic field for cancerization. J Biochem Mol Biol 40: 142-150, 2007.
24. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA and Lübbert M: Demethylation of a hypermethylated P15/ INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964, 2002.
25. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J and Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640, 2003.
26. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
27. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T and Imai K: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606-8613, 2003.
28. Scolnick DM and Halazonetis TD: CHFR defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406: 430-435, 2000.
29. Kang D, Chen J, Wong J and Fang G: The checkpoint protein CHFR is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol 156: 249-259, 2002.
30. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, Ward IM, Saya H, Fang G, van Deursen J and Chen J: CHFR is required for tumor suppression and Aurora A regulation. Nat Genet 37: 401-406, 2005.
31. Ogi K, Toyota M, Mita H, Satoh A, Kashima L, Sasaki Y, Suzuki H, Akino K, Nishikawa N, Noguchi M, Shinomura Y, Imai K, Hiratsuka H and Tokino T: Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors. Cancer Biol Ther 4: 773-780, 2005.
32. Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, Iwata T, Hirasawa A, Fujii T, Susumu N, Tsukazaki K and Aoki D: Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol 31: 713-720, 2007.
33. Koga Y, Kitajima Y, Miyoshi A, Sato K, Sato S and Miyazaki K: The significance of aberrant CHFR methylation for clinical response to microtubule inhibitors in gastric cancer. J Gastroenterol 41: 133-139, 2006.